(Q36788454)

16 August 2017

1 reference

title

Synthetic retinoid fenretinide in breast cancer chemoprevention (English)

1 reference

16 August 2017

Matteo Lazzeroni

2

1 reference

ORCID Public Data File 2021

Umberto Veronesi

series ordinal

3

object named as

Umberto Veronesi

1 reference

16 August 2017

Bernardo Bonanni

1

1 reference

16 August 2017

1 April 2007

1 reference

Expert Review of Anticancer Therapy

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

4

1 reference

16 August 2017

423-432

1 reference

Overview of the main outcomes in breast-cancer prevention trials

16 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

How retinoids regulate breast cancer cell proliferation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

A new class of retinoids with selective inhibition of AP-1 inhibits proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Retinoid receptors in human lung cancer and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Distribution of fenretinide in the mammary gland of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Retinoid therapy of high-risk neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Ceramide synthesis and metabolism as a target for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Inhibition of cancer cell growth by all-trans retinoic acid and its analog N-(4-hydroxyphenyl) retinamide: a possible mechanism of action via regulation of retinoid receptors expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Role of antioxidants and intracellular free radicals in retinamide-induced cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

N-(4-hydroxyphenyl)retinamide inhibits retinoblastoma growth through reactive oxygen species-mediated cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Retinoid modulation of insulin-like growth factor-binding proteins and inhibition of breast carcinoma proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Insulin-like growth factor physiology and cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Role of the insulin-like growth factor family in cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

The role of the IGF system in cancer: from basic to clinical studies and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Serum insulin-like growth factor-I and breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell Cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

A method to assess the proportion of treatment effect explained by a surrogate endpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Retinoid receptors in ovarian cancer: expression and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Effect of fenretinide on ovarian carcinoma occurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.423

21 January 2018

Identifiers

DOI

10.1586/14737140.7.4.423

1 reference

16 August 2017

1 reference

PubMed ID

17428163